#ascvd — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #ascvd, aggregated by home.social.
-
https://www.europesays.com/dk/92351/ Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke #AmericanHeartAssociation #ASCVD #CardiovascularDisease #ChronicKidneyDisease #EuropeanAtherosclerosisSociety #EuropeanHeartJournal #EuropeanSocietyOfCardiology #HeartAttack #HeartFailure #IndependentRiskFactor #inflammation #JacobMartin #KidneyDisease #NovoNordisk #patients
-
https://www.europesays.com/dk/92319/ Novo Nordisk global observational study reveals 2 in 5 #ASCVD #AtheroscleroticDisease #CardiovascularInflammation #ChronicKidneyDisease #CopenhagenStockExchange:NOVOB #CVD #EASCongress #NovoNordisk #NovoNordiskA/S #POSEIDON
-
https://www.europesays.com/dk/92301/ Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke #AmericanHeartAssociation #ASCVD #CardiovascularDisease #ChronicKidneyDisease #EuropeanAtherosclerosisSociety #EuropeanHeartJournal #EuropeanSocietyOfCardiology #HeartAttack #HeartFailure #IndependentRiskFactor #inflammation #JacobMartin #KidneyDisease #NovoNordisk #patients
-
🏀 ASC Ville de Dakar éliminé de la #BAL5
💬 À votre avis, quel bilan tirer et quels enseignements retenir ? -
🏀 ASC Ville de Dakar éliminé de la #BAL5
💬 À votre avis, quel bilan tirer et quels enseignements retenir ? -
🏀 Petro Luanda 76-67 ASCVD (terminé)
❌ Nouvelle défaite pour l’ASC Ville de Dakar ! -
🏀 Petro Luanda 76-67 ASCVD (terminé)
❌ Nouvelle défaite pour l’ASC Ville de Dakar ! -
🏀 ASCVD 65-64 Petro de Luanda (terminé)
🔥 Belle victoire au bout du suspense 💪🏾#ASCVD #PetroDeLuanda #BasketballAfricaLeague #BAL5 #wiwsport
-
🏀 ASCVD 65-64 Petro de Luanda (terminé)
🔥 Belle victoire au bout du suspense 💪🏾#ASCVD #PetroDeLuanda #BasketballAfricaLeague #BAL5 #wiwsport
-
⏸️ ASCVD 33-37 Petro de Luanda (mi-temps)
Les Dakarois sont menés à la pause !🏀 #BAL5
#ASCVD #PetroDeLuanda #BasketballAfricaLeague #wiwsport -
⏸️ ASCVD 33-37 Petro de Luanda (mi-temps)
Les Dakarois sont menés à la pause !🏀 #BAL5
#ASCVD #PetroDeLuanda #BasketballAfricaLeague #wiwsport -
The #LDL cumulative exposure hypothesis: evidence and practical applications | #Nature Reviews #Cardiology https://www.nature.com/articles/s41569-024-01039-5 “Maintaining low levels of LDL-cholesterol (LDL-C) over time decreases the number of LDL particles trapped within the artery wall, slows the progression of atherosclerosis and, by delaying the age at which mature atherosclerotic plaques develop, substantially reduces the lifetime risk of #ASCVD events.”
-
The #LDL cumulative exposure hypothesis: evidence and practical applications | #Nature Reviews #Cardiology https://www.nature.com/articles/s41569-024-01039-5 “Maintaining low levels of LDL-cholesterol (LDL-C) over time decreases the number of LDL particles trapped within the artery wall, slows the progression of atherosclerosis and, by delaying the age at which mature atherosclerotic plaques develop, substantially reduces the lifetime risk of #ASCVD events.”
-
The #LDL cumulative exposure hypothesis: evidence and practical applications | #Nature Reviews #Cardiology https://www.nature.com/articles/s41569-024-01039-5 “Maintaining low levels of LDL-cholesterol (LDL-C) over time decreases the number of LDL particles trapped within the artery wall, slows the progression of atherosclerosis and, by delaying the age at which mature atherosclerotic plaques develop, substantially reduces the lifetime risk of #ASCVD events.”
-
The #LDL cumulative exposure hypothesis: evidence and practical applications | #Nature Reviews #Cardiology https://www.nature.com/articles/s41569-024-01039-5 “Maintaining low levels of LDL-cholesterol (LDL-C) over time decreases the number of LDL particles trapped within the artery wall, slows the progression of atherosclerosis and, by delaying the age at which mature atherosclerotic plaques develop, substantially reduces the lifetime risk of #ASCVD events.”
-
The #LDL cumulative exposure hypothesis: evidence and practical applications | #Nature Reviews #Cardiology https://www.nature.com/articles/s41569-024-01039-5 “Maintaining low levels of LDL-cholesterol (LDL-C) over time decreases the number of LDL particles trapped within the artery wall, slows the progression of atherosclerosis and, by delaying the age at which mature atherosclerotic plaques develop, substantially reduces the lifetime risk of #ASCVD events.”
-
Great intro to @SVM_tweets by @herbaronowMD at the #23FellowsAPP course.
#VascularMedicine so important to #ASCVD management.
@APAC_Cardiology #PhysicianAssociate #HeartPA
-
Great intro to @SVM_tweets by @herbaronowMD at the #23FellowsAPP course.
#VascularMedicine so important to #ASCVD management.
@APAC_Cardiology #PhysicianAssociate #HeartPA
-
Great intro to @SVM_tweets by @herbaronowMD at the #23FellowsAPP course.
#VascularMedicine so important to #ASCVD management.
@APAC_Cardiology #PhysicianAssociate #HeartPA
-
One in three #SouthAsians with #ASCVD on statins are eligible for icosapent ethyl (IPE). IPE should be considered for this high-risk population.
Story I wrote for the #MedicalPost. (Sorry, password protected for #doctors and #pharmacists).Highlights:
A third of South Asians in Canada with known atherosclerotic #cardiovascular disease (ASCVD) and who take #statins would qualify to get additional treatment with icosapent ethyl (IPE).This is a significant-sized population who could benefit from the additional lowering of triglycerides using IPE, according to a study presented at the recent annual meeting of the Canadian Cardiovascular Society (#CCS). This year’s CCS had 1,400 in-person delegates, over 350 online delegates and 130 sessions.
However, a major study, the REDUCE-IT trial driving the use of IPE had very few non-white participants, according to a poster abstract presented by Canadian researchers.
IPE is a highly purified preparation of #eicosapentaenoic acid (EPA), which is an omega-3 fatty acid. It is used to treat severe hypertriglyceridemia (500 mg/dL and over). It is used as an adjunct to statin therapy to reduce the risk of cardiovascular events in people whose serum #triglyceride levels are over 150 mg/dL.
#MedMastodon -
One in three #SouthAsians with #ASCVD on statins are eligible for icosapent ethyl (IPE). IPE should be considered for this high-risk population.
Story I wrote for the #MedicalPost. (Sorry, password protected for #doctors and #pharmacists).Highlights:
A third of South Asians in Canada with known atherosclerotic #cardiovascular disease (ASCVD) and who take #statins would qualify to get additional treatment with icosapent ethyl (IPE).This is a significant-sized population who could benefit from the additional lowering of triglycerides using IPE, according to a study presented at the recent annual meeting of the Canadian Cardiovascular Society (#CCS). This year’s CCS had 1,400 in-person delegates, over 350 online delegates and 130 sessions.
However, a major study, the REDUCE-IT trial driving the use of IPE had very few non-white participants, according to a poster abstract presented by Canadian researchers.
IPE is a highly purified preparation of #eicosapentaenoic acid (EPA), which is an omega-3 fatty acid. It is used to treat severe hypertriglyceridemia (500 mg/dL and over). It is used as an adjunct to statin therapy to reduce the risk of cardiovascular events in people whose serum #triglyceride levels are over 150 mg/dL.
#MedMastodon -
One in three #SouthAsians with #ASCVD on statins are eligible for icosapent ethyl (IPE). IPE should be considered for this high-risk population.
Story I wrote for the #MedicalPost. (Sorry, password protected for #doctors and #pharmacists).Highlights:
A third of South Asians in Canada with known atherosclerotic #cardiovascular disease (ASCVD) and who take #statins would qualify to get additional treatment with icosapent ethyl (IPE).This is a significant-sized population who could benefit from the additional lowering of triglycerides using IPE, according to a study presented at the recent annual meeting of the Canadian Cardiovascular Society (#CCS). This year’s CCS had 1,400 in-person delegates, over 350 online delegates and 130 sessions.
However, a major study, the REDUCE-IT trial driving the use of IPE had very few non-white participants, according to a poster abstract presented by Canadian researchers.
IPE is a highly purified preparation of #eicosapentaenoic acid (EPA), which is an omega-3 fatty acid. It is used to treat severe hypertriglyceridemia (500 mg/dL and over). It is used as an adjunct to statin therapy to reduce the risk of cardiovascular events in people whose serum #triglyceride levels are over 150 mg/dL.
#MedMastodon -
One in three #SouthAsians with #ASCVD on statins are eligible for icosapent ethyl (IPE). IPE should be considered for this high-risk population.
Story I wrote for the #MedicalPost. (Sorry, password protected for #doctors and #pharmacists).Highlights:
A third of South Asians in Canada with known atherosclerotic #cardiovascular disease (ASCVD) and who take #statins would qualify to get additional treatment with icosapent ethyl (IPE).This is a significant-sized population who could benefit from the additional lowering of triglycerides using IPE, according to a study presented at the recent annual meeting of the Canadian Cardiovascular Society (#CCS). This year’s CCS had 1,400 in-person delegates, over 350 online delegates and 130 sessions.
However, a major study, the REDUCE-IT trial driving the use of IPE had very few non-white participants, according to a poster abstract presented by Canadian researchers.
IPE is a highly purified preparation of #eicosapentaenoic acid (EPA), which is an omega-3 fatty acid. It is used to treat severe hypertriglyceridemia (500 mg/dL and over). It is used as an adjunct to statin therapy to reduce the risk of cardiovascular events in people whose serum #triglyceride levels are over 150 mg/dL.
#MedMastodon -
One in three #SouthAsians with #ASCVD on statins are eligible for icosapent ethyl (IPE). IPE should be considered for this high-risk population.
Story I wrote for the #MedicalPost. (Sorry, password protected for #doctors and #pharmacists).Highlights:
A third of South Asians in Canada with known atherosclerotic #cardiovascular disease (ASCVD) and who take #statins would qualify to get additional treatment with icosapent ethyl (IPE).This is a significant-sized population who could benefit from the additional lowering of triglycerides using IPE, according to a study presented at the recent annual meeting of the Canadian Cardiovascular Society (#CCS). This year’s CCS had 1,400 in-person delegates, over 350 online delegates and 130 sessions.
However, a major study, the REDUCE-IT trial driving the use of IPE had very few non-white participants, according to a poster abstract presented by Canadian researchers.
IPE is a highly purified preparation of #eicosapentaenoic acid (EPA), which is an omega-3 fatty acid. It is used to treat severe hypertriglyceridemia (500 mg/dL and over). It is used as an adjunct to statin therapy to reduce the risk of cardiovascular events in people whose serum #triglyceride levels are over 150 mg/dL.
#MedMastodon